<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057107</url>
  </required_header>
  <id_info>
    <org_study_id>11-112</org_study_id>
    <nct_id>NCT02057107</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)</brief_title>
  <official_title>Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David A. Clump, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the overall survival of patients with the addition of docetaxel to the overall&#xD;
      survival of patients treated with SBRT and cetuximab alone. In addition, we will determine&#xD;
      the difference in progression free survival (PFS), the rate of local recurrence (LR) and of&#xD;
      distant metastases (DM) across the SBRT and cetuximab + docetaxel arm and the arm receiving&#xD;
      SBRT and cetuximab alone. To better resolve the impact of the experimental treatment on PFS,&#xD;
      LR, and DM, patients will be stratified by the presence/absence of prior cetuximab treatment&#xD;
      and then randomized to either the control arm (cetuximab and SBRT only) or the experimental&#xD;
      arm (cetuximab, SBRT, and docetaxel).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional progression-free survival (PFS) of previously-irradiated patients with SCCHN treated with SBRT, cetuximab, and docetaxel</measure>
    <time_frame>1 Year</time_frame>
    <description>Evaluated by PET/CT or CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicities associated with the above therapy</measure>
    <time_frame>3 years</time_frame>
    <description>Determined by patient follow up CTCAE criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Recurrent</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously Treated With Cetuximab - Group A No Previous Cetuximab - Group C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SBRT + Cetuximab followed by Cetuximab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Previously Treated with Cetuximab - Group B No Previous Cetuximab - Group D</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>8.8-10 Gy per fraction (total: 44-50 Gy)</description>
    <arm_group_label>SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel</arm_group_label>
    <arm_group_label>SBRT + Cetuximab followed by Cetuximab</arm_group_label>
    <other_name>Radiosurgery</other_name>
    <other_name>Stereotactic radiosurgery</other_name>
    <other_name>CyberKnife</other_name>
    <other_name>True Beam</other_name>
    <other_name>Trilogy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Day -7 (One week prior to commencement of stereotactic radiosurgery):&#xD;
Cetuximab, 400 mg/m2&#xD;
Days 0 and 8 (The 1st and 2nd week of radiosurgery):&#xD;
Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)</description>
    <arm_group_label>SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel</arm_group_label>
    <arm_group_label>SBRT + Cetuximab followed by Cetuximab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)</description>
    <arm_group_label>SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-proven recurrent squamous cell carcinoma of the head and neck (SCCHN),&#xD;
             who has received prior radiotherapy with or without chemotherapy. New primary is&#xD;
             allowed if location is in a previously irradiated field. Biopsy is recommended for&#xD;
             each recurrence but is not mandated per study. This will be at the discretion of the&#xD;
             principal investigator.&#xD;
&#xD;
          -  Prior radiation dose of at least 50 Gy.&#xD;
&#xD;
          -  Disease confined to locoregional site and can be encompassed in a stereotactic body&#xD;
             radiosurgery &quot;portal&quot;&#xD;
&#xD;
          -  Tumor must be deemed to be inoperable or unresectable either by clinical or&#xD;
             radiographic criteria. These criteria include encasement of great vessels, vertebral&#xD;
             invasion or undue peri-operative risk.&#xD;
&#xD;
          -  Prior surgery for recurrent or new SCCHN is allowed in previously irradiated patients.&#xD;
             A minimum of 4 weeks should elapse between any surgery and treatment on study.&#xD;
             However, high-risk pathologic features should be present, such as positive margins,&#xD;
             positive lymphadenopathy, perineural or angiolymphatic invasion.&#xD;
&#xD;
          -  Karnofsky performance status &gt; 60 (ECOG 0-1)&#xD;
&#xD;
          -  Prior treatment with an EGFR Inhibitor is allowed if it was a part of prior curative&#xD;
             therapy and was completed at least 30 days prior to commencement of study therapy&#xD;
&#xD;
          -  Any number of prior chemotherapy regimens are allowed&#xD;
&#xD;
          -  Measurable disease on imaging studies (MRI, CT, PET-CT or physical exam)&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Estimated life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  No prior radiation therapy or chemotherapy within 1 month of study enrollment&#xD;
&#xD;
          -  ANC &gt; 1000, PLT&gt;75,000, Serum creatinine&lt;2.5 mg/dL, Bilirubin &lt;1.5 x upper limits of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Diabetes must be controlled prior to PET-CT scanning (blood glucose &lt;200 mg/dL)&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT)&#xD;
             or other staging studies&#xD;
&#xD;
          -  Patients in their reproductive age group should use an effective method of birth&#xD;
             control. Patients who are breast-feeding, or have a positive pregnancy test will be&#xD;
             excluded from the study&#xD;
&#xD;
          -  Any co-morbidity or condition of sufficient severity to limit full compliance with the&#xD;
             protocol per assessment by the investigator&#xD;
&#xD;
          -  Concurrent serious infection&#xD;
&#xD;
          -  History of known hypersensitivity to cetuximab, docetaxel or similar agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dwight E Heron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen D Holeva, BS</last_name>
    <phone>412-623-1275</phone>
    <email>holevakd@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dwight E Heron, MD</last_name>
    <phone>412-623-6720</phone>
    <email>herond2@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Shadyside Radiation Oncology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen D Holeva, BS</last_name>
      <phone>412-623-1275</phone>
      <email>holevakd@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dwight E Heron, MD</last_name>
      <phone>412-623-6720</phone>
      <email>herond2@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David A Clump, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Burton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian J Karlovits, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Ferris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Ohr, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Bauman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dwight E Heron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 30, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>David A. Clump, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

